The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials
This study aims to assess the efficacy and safety of doripenem on treating patients with acute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April 2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment of acute bacteri...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/7/958 |
id |
doaj-88550d7015ad4eef84ff723ebeb02f11 |
---|---|
record_format |
Article |
spelling |
doaj-88550d7015ad4eef84ff723ebeb02f112020-11-24T21:31:46ZengMDPI AGJournal of Clinical Medicine2077-03832019-07-018795810.3390/jcm8070958jcm8070958The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled TrialsChih-Cheng Lai0I-Ling Cheng1Yu-Hung Chen2Hung-Jen Tang3Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying 73657, TaiwanDepartment of Pharmacy, Chi Mei Medical Center, Liouying 73657, TaiwanDepartment of Pharmacy, Chi Mei Medical Center, Liouying 73657, TaiwanDepartment of Medicine, Chi Mei Medical Center, Tainan 71004, TaiwanThis study aims to assess the efficacy and safety of doripenem on treating patients with acute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April 2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment of acute bacterial infection were included. The primary outcome was the clinical success rate and the secondary outcomes were microbiological eradication rate and risk of adverse events. Eight randomized controlled trials (RCTs) were included. Overall, doripenem had a similar clinical success rate with comparators (odds ratio [OR], 1.15; 95% CI, 0.79–1.66, I2 = 58%). Similar clinical success rates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46–1.53, <i>I</i><sup>2</sup> = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57–1.72). For complicated urinary tract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95% CI, 1.13–3.17, <i>I</i><sup>2</sup> = 0%). The pool analysis comparing doripenem and other carbapenems showed no significant differences between each other (OR, 0.96, 95% CI, 0.59–1.58, <i>I</i><sup>2</sup> = 63%). Doripenem also had a similar microbiological eradication rate with comparators (OR, 1.08; 95% CI, 0.86–1.36, <i>I</i><sup>2</sup> = 0%). Finally, doripenem had a similar risk of treatment-emergent adverse events as comparators (OR, 0.98; 95% CI, 0.83–1.17, <i>I</i><sup>2</sup> = 33%). In conclusion, the clinical efficacy of doripenem is as high as that of the comparator drugs in the treatment of acute bacterial infection; furthermore, this antibiotic is as well tolerated as the comparators.https://www.mdpi.com/2077-0383/8/7/958doripenemacute bacterial infectionpneumoniaintra-abdominal infectioncomplicated urinary tract infection |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Chih-Cheng Lai I-Ling Cheng Yu-Hung Chen Hung-Jen Tang |
spellingShingle |
Chih-Cheng Lai I-Ling Cheng Yu-Hung Chen Hung-Jen Tang The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials Journal of Clinical Medicine doripenem acute bacterial infection pneumonia intra-abdominal infection complicated urinary tract infection |
author_facet |
Chih-Cheng Lai I-Ling Cheng Yu-Hung Chen Hung-Jen Tang |
author_sort |
Chih-Cheng Lai |
title |
The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_short |
The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_full |
The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_fullStr |
The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_full_unstemmed |
The Efficacy and Safety of Doripenem in the Treatment of Acute Bacterial Infections—A Systemic Review and Meta-Analysis of Randomized Controlled Trials |
title_sort |
efficacy and safety of doripenem in the treatment of acute bacterial infections—a systemic review and meta-analysis of randomized controlled trials |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2019-07-01 |
description |
This study aims to assess the efficacy and safety of doripenem on treating patients with acute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April 2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment of acute bacterial infection were included. The primary outcome was the clinical success rate and the secondary outcomes were microbiological eradication rate and risk of adverse events. Eight randomized controlled trials (RCTs) were included. Overall, doripenem had a similar clinical success rate with comparators (odds ratio [OR], 1.15; 95% CI, 0.79–1.66, I2 = 58%). Similar clinical success rates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46–1.53, <i>I</i><sup>2</sup> = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57–1.72). For complicated urinary tract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95% CI, 1.13–3.17, <i>I</i><sup>2</sup> = 0%). The pool analysis comparing doripenem and other carbapenems showed no significant differences between each other (OR, 0.96, 95% CI, 0.59–1.58, <i>I</i><sup>2</sup> = 63%). Doripenem also had a similar microbiological eradication rate with comparators (OR, 1.08; 95% CI, 0.86–1.36, <i>I</i><sup>2</sup> = 0%). Finally, doripenem had a similar risk of treatment-emergent adverse events as comparators (OR, 0.98; 95% CI, 0.83–1.17, <i>I</i><sup>2</sup> = 33%). In conclusion, the clinical efficacy of doripenem is as high as that of the comparator drugs in the treatment of acute bacterial infection; furthermore, this antibiotic is as well tolerated as the comparators. |
topic |
doripenem acute bacterial infection pneumonia intra-abdominal infection complicated urinary tract infection |
url |
https://www.mdpi.com/2077-0383/8/7/958 |
work_keys_str_mv |
AT chihchenglai theefficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT ilingcheng theefficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT yuhungchen theefficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT hungjentang theefficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT chihchenglai efficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT ilingcheng efficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT yuhungchen efficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials AT hungjentang efficacyandsafetyofdoripeneminthetreatmentofacutebacterialinfectionsasystemicreviewandmetaanalysisofrandomizedcontrolledtrials |
_version_ |
1725959848823095296 |